• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Nov. 9

Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration for two abbreviated new drug applications (ANDAs) – Cefotaxime for injection (in 500 mg, 1g and 2g) and cefotaxime injection in 10g pharmacy bulk pack, the Hyderabad-based company informed BSE. Cefotaxime for injection is the generic equivalent to Claforan for injection of Sanofi Aventis US. It falls under the anti-betallactum segment. The product was ready for launch, it said. —

Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line